Port Therapeutics is a pre-clinical stage biotechnology company developing spatiotemporal control for cell therapies and immunotherapies. Co-founded by Catalio Capital Venture Partner Sangeeta Bhatia.

Port has developed a proprietary thermal bio switch that can be used to selectively activate cells in vivo with a non-invasive Focused Ultrasound. Historically, gene switches were triggered by small molecules, proteins, and light, all of which were limited to the depth they could reach within a tissue. Thermal bio switches can be delivered noninvasively with millimeter precision and at depth to anatomical sites. Port will use their technology to develop the next generation of cell therapies.